Compare
Niagen Bioscience, Inc. vs Natural Alternatives International Inc vs Cronos Group Inc. vs Mannatech Inc
| Latest fiscal year | Niagen Bioscience, Inc. NAGE | Natural Alternatives International Inc NAII | Cronos Group Inc. CRON | Mannatech Inc MTEX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $129.42M | $129.86M | $146.59M | $108.04M |
| Revenue growth (YoY) | +29.9% | +14.1% | +24.6% | -8.3% |
| Gross margin | 64.3% | 7.2% | 42.8% | 74.9% |
| Operating margin | 12.6% | -6.7% | -11.9% | -0.4% |
| Net margin | 13.4% | -10.5% | -6.4% | -14.1% |
| Net income | $17.38M | -$13.57M | -$9.45M | -$15.21M |
| EPS (Diluted) | $0.20 | -$2.28 | -$0.02 | -$8.00 |
| Operating cash flow | $13.50M | $5.93M | $25.87M | -$2.96M |
| Free cash flow | n/a | $2.32M | $149.0K | -$4.32M |
| Cash & equivalents | n/a | $12.32M | $791.79M | $6.18M |
| Total assets | $106.41M | $151.94M | $1.20B | $29.99M |
| Total liabilities | $29.87M | $83.51M | $54.18M | $35.22M |
| Shareholders' equity | $76.53M | $68.43M | $1.14B | -$5.22M |
| Return on year-end equity | 22.7% | -19.8% | -0.8% | n/a |
| Shares outstanding | 79.71M | 6.18M | 381.59M | 1.90M |
Revenue, most recent five fiscal years
| Fiscal year | Niagen Bioscience, Inc. | Natural Alternatives International Inc | Cronos Group Inc. | Mannatech Inc |
|---|---|---|---|---|
| Latest | $129.42M Ended 2025-12-31 | $129.86M Ended 2025-06-30 | $146.59M Ended 2025-12-31 | $108.04M Ended 2025-12-31 |
| 1 year earlier | $99.60M Ended 2024-12-31 | $113.80M Ended 2024-06-30 | $117.61M Ended 2024-12-31 | $117.87M Ended 2024-12-31 |
| 2 years earlier | $83.57M Ended 2023-12-31 | $154.01M Ended 2023-06-30 | $87.24M Ended 2023-12-31 | $131.96M Ended 2023-12-31 |
| 3 years earlier | $72.05M Ended 2022-12-31 | $170.97M Ended 2022-06-30 | $86.75M Ended 2022-12-31 | $137.21M Ended 2022-12-31 |
| 4 years earlier | $67.45M Ended 2021-12-31 | $178.52M Ended 2021-06-30 | $64.56M Ended 2021-12-31 | $159.76M Ended 2021-12-31 |